To support drug discovery projects in oncology, we perform high-content analysis either in cellular models of human tumors in 2D or 3D, or directly in tumor tissues and blood samples. Combining a panel of validated assays for immediate performance and more than 10-year experience in assay development, we assist pharmaceutical companies and academic researchers in the discovery of new cancer drug targets, the identification of new anticancer compounds, and the quantitative analysis of novel cancer biomarkers.

IN VIVO TUMOR MODELS FOR CANCER IMMUNOTHERAPY

In recent years, a number of immune checkpoint inhibitors have been granted FDA approval. Although efficient, monoclonal antibodies targeting immune checkpoints have been found to produce objective and durable anti-tumor response in a limited number of cancer patients. To identify novel therapeutic strategies capable of enhancing the efficacy of immune checkpoint inhibitors, Fluofarma offers validated syngeneic mouse tumor model of anti-CTLA-4 and anti-PD-L1 immunotherapies.­­

FLUOFARMA'S ADDED VALUE

Fast study initiation and weekly reports: syngeneic tumor models are set up and ready for treatment within 15 to 20 days after proposal validation. Preliminary reports are then are communicated every week.